International Dermatology Outcome Measures (IDEOM): A Report From the 2023 Annual Meeting
December 2024 | Volume 23 | Issue 12 | 1114 | Copyright © December 2024
Published online November 29, 2024
Arianna J. Zhang BAa*, Gretchen Ball BSb*, Melissa P. Zundell BSb, Rosario Agüero MDc, Danielle Yee MDd, Ali Shields BAe, Christina Asare BSf, Kristina Navrazhina MD PhDb, Winston Liu PhDg, Negar Foolad MD MASg, Jeffery Kwock MDg, Priyanka Tejwani BSg, Hassan Hamade b, Tarannum Jaleel MDg, Daniel Butler MDh, Nanette Silverberg MDb, Leigh Nattkemper PhDi, Daniel M. Siegel MD MA FAADj,k, Jerry Tan MDl, Brian S. Kim MD MTRb, Cecilia Larocca MDa, Michi M. Shinohara MDf, Athena Ehlert m, John Latella m, Emma Guttman-Yassky b, James G. Krueger n, Vibeke Strand MDo, April W. Armstrong MD MPHd, Joseph F. Merola MD MMSca, Lourdes Perez-Chada MD MMSca**, Alice B. Gottlieb MD PhDb**
aDepartment of Dermatology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
bDepartment of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY
cDepartment of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles, CA
dDivision of Dermatology, David Geffen School of Medicine at the University of California-Los Angeles, Los Angeles, CA
eDrexel University College of Medicine, Philadelphia, PA
fDivision of Dermatology, University of Washington,
Fred Hutchinson Cancer Center, Seattle, WA
gDepartment of Dermatology, Duke University School of Medicine, Durham, NC
hDivision of Dermatology, University of Arizona, Tucson, AZ
iDr. Phillip Frost Department of Dermatology and Cutaneous Surgery and Miami Itch Center, the University of Miami Miller School of Medicine, Miami, FL
jDepartment of Dermatology, SUNY Downstate Medical Center, Brooklyn, NY
kDepartment of Dermatology, VA New York Harbor Healthcare System, Brooklyn, NY
lWestern University Canada, Schulich School of Medicine and Dentistry, Ontario, Canada
mInternational Dermatology Outcome Measures, Roseville, CA; nLaboratory for Investigative Dermatology, The Rockefeller University, New York, NY
oDivision of Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, CA
Abstract
Background: International Dermatology Outcome Measures (IDEOM) is a non-profit organization whose mission is to improve the availability of evidence-based, consensus-driven outcome measures for dermatological diseases. IDEOM facilitates collaboration between stakeholders from various backgrounds, including researchers, patients, physicians, and industry representatives, to develop objective benchmark metrics that enable better treatment and management of dermatologic conditions.
Summary: The 2023 IDEOM Annual Meeting was held June 23-24, 2023. Workgroups in psoriatic disease, hidradenitis suppurativa, geriatric dermatology, connective tissue disease, vitiligo, itch, actinic keratosis, acne, and cutaneous T-cell lymphoma discussed the progress of their respective outcome-measures research. This report summarizes each workgroup’s updates since the 2022 annual meeting and their next steps as established during the 2023 IDEOM Annual Meeting.
J Drugs Dermatol. 2024;23(12):1114-1120. doi:10.36849/JDD.8363
INTRODUCTION
The International Dermatology Outcome Measures (IDEOM) initiative is a non-profit organization founded in 2013 to enhance research and treatment of dermatologic disease by addressing a need for validated, standardized, patient-centered outcome measures in dermatology.1 IDEOM seeks to develop comprehensive, cost-free outcome measures that satisfy the needs of patients, physicians, researchers, government, industry, and non-profit stakeholders.
Each year, IDEOM stakeholders collaborate in dedicated workgroups to review progress, present projects, and discuss future research plans. These workgroups include psoriatic disease, hidradenitis suppurativa, geriatric dermatology, connective tissue disease, vitiligo, itch, actinic keratosis, acne, and cutaneous T-cell lymphoma. Additionally, IDEOM provides teaching sessions on outcome measure development and validation for patients and advocates for the patient's voice.
